Alexion Pharmaceuticals Inc

$ 117.93 0.69 (0.59%)
On watch
Volume: 961,254 Avg Vol (1m): 1,396,975
Market Cap $: 26.44 Bil Enterprise Value $: 27.39 Bil
P/E (TTM): 64.44 P/B: 2.74
Earnings Power Value 32.89
Net Current Asset Value -2.85
Tangible Book 4.92
Projected FCF 69.86
Median P/S Value 255.35
Graham Number 14.23
Peter Lynch Value 0
DCF (FCF Based) 45.72
DCF (Earnings Based) 22.53
1Y (-%)

Financial Strength : 7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.64
Cash-To-Debt ranked lower than
89.70% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ALXN: 0.64
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.32, Med: 2.56, Max: 10000
Current: 0.64
0.32
10000
Equity-to-Asset 0.69
Equity-to-Asset ranked lower than
53.60% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ALXN: 0.69
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.04, Med: 0.66, Max: 0.95
Current: 0.69
0.04
0.95
Debt-to-Equity 0.27
Debt-to-Equity ranked lower than
58.40% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
ALXN: 0.27
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.33, Max: 17.46
Current: 0.27
0
17.46
Debt-to-EBITDA 2.80
Debt-to-EBITDA ranked lower than
77.04% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
ALXN: 2.8
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: 0.03, Med: 0.35, Max: 4.8
Current: 2.8
0.03
4.8
Interest Coverage 18.79
Interest Coverage ranked lower than
85.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ALXN: 18.79
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 8.17, Med: 99.52, Max: 310.04
Current: 18.79
8.17
310.04
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.64
DISTRESS
GREY
SAFE
Beneish M-Score -1.84
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 16.24%
WACC 11.8%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 40.69
Operating Margin ranked higher than
91.54% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ALXN: 40.69
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 22.51, Med: 29.58, Max: 41
Current: 40.69
22.51
41
Net Margin % 9.59
Net Margin ranked higher than
70.58% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ALXN: 9.59
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 1.88, Med: 17.12, Max: 76.31
Current: 9.59
1.88
76.31
ROE % 4.53
ROE ranked higher than
76.24% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ALXN: 4.53
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 0.86, Med: 12.08, Max: 63.11
Current: 4.53
0.86
63.11
ROA % 3.01
ROA ranked higher than
77.86% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ALXN: 3.01
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 0.56, Med: 9.66, Max: 46.71
Current: 3.01
0.56
46.71
ROC (Joel Greenblatt) % 22.58
ROC (Joel Greenblatt) ranked higher than
81.76% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ALXN: 22.58
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 15.19, Med: 54.99, Max: 173.84
Current: 22.58
15.19
173.84
3-Year Total Revenue Growth Rate 16.60
3-Year Revenue Growth Rate ranked higher than
68.97% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
ALXN: 15.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: 24.45, Max: 462.4
Current: 15.1
0
462.4
3-Year Total EBITDA Growth Rate 1.50
3-Year EBITDA Growth Rate ranked lower than
50.87% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ALXN: 0.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -3, Max: 73.2
Current: 0.2
0
73.2
3-Year EPS w/o NRI Growth Rate -19.50
3-Year EPS w/o NRI Growth Rate ranked lower than
71.69% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ALXN: -19.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» ALXN's 30-Y Financials

Financials (Next Earnings Date: 2019-07-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ALXN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 541714    SIC : 8731
Compare NAS:REGN XKRX:068270 NAS:INCY XKRX:207940 NAS:BMRN XBRU:UCB OCSE:NZYM B NAS:VRTX HKSE:01177 HKSE:02269 OCSE:GEN NAS:SGEN NAS:IONS NAS:SAGE NAS:SRPT NAS:JAZZ HKSE:06160 NAS:TECH NAS:ALNY SZSE:000661
Traded in other countries AXP.Germany 0QZM.UK
Address 121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Ratios

Current vs industry vs history
PE Ratio (TTM) 64.44
PE Ratio ranked lower than
100.00% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
ALXN: 64.44
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 13.83, Med: 73.48, Max: 961.82
Current: 64.44
13.83
961.82
Forward PE Ratio 12.39
Forward P/E ranked higher than
68.83% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
ALXN: 12.39
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 64.44
PE without NRI ranked lower than
100.00% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
ALXN: 64.44
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 13.83, Med: 73.48, Max: 961.82
Current: 64.44
13.83
961.82
PB Ratio 2.74
PB Ratio ranked higher than
60.81% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ALXN: 2.74
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.31, Med: 8.76, Max: 28.45
Current: 2.74
2.31
28.45
PS Ratio 6.10
PS Ratio ranked higher than
62.53% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ALXN: 6.1
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 5.13, Med: 13.21, Max: 23.44
Current: 6.1
5.13
23.44
Price-to-Free-Cash-Flow 73.43
Price-to-Free-Cash-Flow ranked lower than
84.87% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
ALXN: 73.43
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 25.23, Med: 61.83, Max: 4990
Current: 73.43
25.23
4990
Price-to-Operating-Cash-Flow 48.02
Price-to-Operating-Cash-Flow ranked lower than
71.43% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
ALXN: 48.02
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 18.13, Med: 47.32, Max: 83.95
Current: 48.02
18.13
83.95
EV-to-EBIT 52.02
EV-to-EBIT ranked lower than
92.34% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ALXN: 52.02
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -98.6, Med: 49.4, Max: 893.9
Current: 52.02
-98.6
893.9
EV-to-EBITDA 29.53
EV-to-EBITDA ranked lower than
76.51% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ALXN: 29.53
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -119, Med: 42.3, Max: 334.6
Current: 29.53
-119
334.6
EV-to-Revenue 6.31
EV-to-Revenue ranked higher than
62.91% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ALXN: 6.31
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 5.5, Med: 13.5, Max: 23.3
Current: 6.31
5.5
23.3
PEG Ratio 14.31
PEG Ratio ranked lower than
100.00% of 115 companies
in the Biotechnology industry.
Industry Max: 99.55, Med: 2.02, Min: 0.06
ALXN: 14.31
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 0.68, Med: 2.72, Max: 80.39
Current: 14.31
0.68
80.39
Shiller PE Ratio 67.57
Shiller PE Ratio ranked lower than
74.42% of 86 companies
in the Biotechnology industry.
Industry Max: 11472.38, Med: 42.91, Min: 0.02
ALXN: 67.57
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 64.82, Med: 139.91, Max: 1466
Current: 67.57
64.82
1466
Current Ratio 3.87
Current Ratio ranked lower than
66.39% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ALXN: 3.87
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.38, Med: 5.48, Max: 52.92
Current: 3.87
1.38
52.92
Quick Ratio 3.36
Quick Ratio ranked lower than
67.78% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ALXN: 3.36
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.38, Med: 4.9, Max: 52.92
Current: 3.36
1.38
52.92
Days Inventory 457.04
Days Inventory ranked lower than
86.28% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
ALXN: 457.04
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 202.61, Med: 350.37, Max: 469.64
Current: 457.04
202.61
469.64
Days Sales Outstanding 85.46
Days Sales Outstanding ranked lower than
63.77% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
ALXN: 85.46
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 70.73, Med: 88.31, Max: 113.85
Current: 85.46
70.73
113.85
Days Payable 663.44
Days Payable ranked lower than
62.69% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
ALXN: 663.44
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 44.39, Med: 89.92, Max: 663.44
Current: 663.44
44.39
663.44

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 0.30
3-Year Share Buyback Rate ranked higher than
80.98% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ALXN: 0.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -24.9, Med: -7.2, Max: 0.3
Current: 0.3
-24.9
0.3

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 23.99
Price-to-Tangible-Book ranked lower than
100.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ALXN: 23.99
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.13, Med: 10.21, Max: 123.3
Current: 23.99
1.13
123.3
Price-to-Projected-FCF 1.69
Price-to-Intrinsic-Value-Projected-FCF ranked higher than
67.36% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
ALXN: 1.69
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.49, Med: 4.98, Max: 142.22
Current: 1.69
1.49
142.22
Price-to-DCF (Earnings Based) 5.23
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
100.00% of 38 companies
in the Biotechnology industry.
Industry Max: 12.19, Med: 1.7, Min: 0.43
ALXN: 5.23
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 6, Med: 14.99, Max: 23.98
Current: 5.23
6
23.98
Price-to-Median-PS-Value 0.46
Price-to-Median-PS-Value ranked higher than
79.20% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ALXN: 0.46
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.4, Med: 1.3, Max: 63.13
Current: 0.46
0.4
63.13
Price-to-Graham-Number 8.29
Price-to-Graham-Number ranked lower than
100.00% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
ALXN: 8.29
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 2.05, Med: 6.91, Max: 28.9
Current: 8.29
2.05
28.9
Earnings Yield (Joel Greenblatt) % 1.92
Earnings Yield (Greenblatt) ranked higher than
77.80% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ALXN: 1.92
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1.4, Med: 2, Max: 3.2
Current: 1.92
-1.4
3.2
Forward Rate of Return (Yacktman) % 4.91
Forward Rate of Return ranked higher than
51.85% of 135 companies
in the Biotechnology industry.
Industry Max: 107.61, Med: 11.41, Min: -475.79
ALXN: 4.91
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: -18.5, Med: 8.95, Max: 22.5
Current: 4.91
-18.5
22.5

More Statistics

Revenue (TTM) (Mil) $ 4,340.7
EPS (TTM) $ 1.83
Beta 1.79
Volatility % 50.31
52-Week Range $ 92.56 - 141.86
Shares Outstanding (Mil) 224.24

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y